CBD is not a controlled substance in Hungary, and the authority that is responsible for CBD-related products depends entirely on their intended purpose. This report covers a wide range of aspects including hemp cultivation and disposal, extracts and finished products, imports and exports, and medical and recreational cannabis, including the numerous laws and relevant bodies that are involved in the enforcement and regulation of each.
If you purchase a report that is updated in the next 60 days, we will send you the new report for free.
Reasons to buyThis report will provide you with a deeper understanding of the current regulatory landscape in Hungary. The country takes an especially tough stance on cannabis, with no indication of the possibility of a medical cannabis programme being introduced, as is the case for many other EU countries. This report will enable you to obtain a detailed knowledge of all aspects of Hungary’s CBD regime.
Table of contents
MethodologyThe research is completely original and conducted by CBD-Intel’s multilingual legal analysis team using several sources, including: online and offline resources and data, specialised legal software, interviews with key stakeholders and government officials, and via the collaboration with local lawyers and on-the-ground profession.
Latest reportsCBD is not a controlled substance in Hungary, and the authority that is responsible for CBD-related products depends entirely on their intended purpose. This report covers a wide range of aspects including hemp cultivation and disposal, extracts and finished products, imports and exports, and medical and recreational cannabis, including the numerous laws and relevant bodies that are involved in the enforcement and regulation of each.
Check out our new regulatory data on medical and recreational cannabis in 54 jurisdictions around the world
The report, accompanied by a more detailed database, provides an overview of the regulatory situation in the selected countries, using maps, and assesses the likelihood that the status quo may change in the future.
Available for purchase
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.